American Journal of Clinical Dermatology

, Volume 14, Issue 1, pp 49–53 | Cite as

Principal Determinants of the Length of Remission of Psoriasis Vulgaris After Topical, NB-UVB, and PUVA Therapy

A Follow-Up Study
  • Susana Coimbra
  • Hugo Oliveira
  • Luís Belo
  • Américo Figueiredo
  • Petronila Rocha-Pereira
  • Alice Santos-Silva
Short Communication



Periods of remission and of exacerbation of psoriatic lesions are common in psoriasis. We recently reported C-reactive protein (CRP) as a marker of psoriasis severity and that some patients still presented with a residual inflammation after treatment. We wondered if this residual inflammation could underlie an earlier exacerbation of psoriasis.


The purpose of our study was to evaluate if there is a relationship between CRP levels, Psoriasis Area and Severity Index (PASI), and body mass index (BMI), at the end of psoriasis treatment, with the length of psoriasis remission.


We followed 46 patients studied at the end of treatment, to record the length of remission; 9 of the patients were treated with topical agents, 17 with narrow-band UVB (NB-UVB), and 20 with psoralen plus UVA (PUVA).


We found that the length of remission correlated with the values for PASI and CRP at the end of therapy. By performing a multiple linear regression analysis, CRP, PASI, and BMI were each significantly associated with length of remission. Patients with residual inflammation at the end of treatment presented with a significantly shorter length of remission. When considering patients grouped according to the used therapies, CRP and PASI also emerged as potential determinants of length of remission, especially in the case of patients treated with NB-UVB and topical therapy.


Our data suggest that CRP and PASI are important determinants of length of psoriasis remission for patients treated with phototherapy or topical therapy. Further studies with larger groups of patients are warranted to test this hypothesis. Moreover, we propose that, by the end of the treatment, the evaluation of CRP and PASI could be important to decide, when possible, if the treatment should be continued to achieve lower CRP values and longer periods of remission.


Psoriasis Multiple Linear Regression Analysis Topical Agent Topical Therapy Calcipotriol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by Fundação para a Ciência e Tecnologia (FCT: POCI/SAU–OBS/58600/2004) and Fundo Europeu de Desenvolvimento Regional (FEDER). The authors have no financial or other relations that could lead to conflict of interest; all authors state no conflict of interest.


  1. 1.
    Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41(1):51–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150(5):917–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(7):789–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(12):1386–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55(3):202–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101(8):1119–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211(2):103–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11(6):423–32.PubMedCrossRefGoogle Scholar
  10. 10.
    van de Kerkhof PC. On the limitations of the psoriasis area and severity index (PASI). Br J Dermatol. 1992;126(2):205.PubMedCrossRefGoogle Scholar
  11. 11.
    Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51(4):563–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:ii65–8 (discussion ii9–73).Google Scholar
  13. 13.
    Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, et al. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: “right-left intra-individual pre/post comparison design”. Int J Immunopathol Pharmacol. 2005;18(4):755–60.PubMedGoogle Scholar
  14. 14.
    Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM. Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. Dermatology. 2001;202(2):108–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142(7):836–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  • Susana Coimbra
    • 1
    • 2
  • Hugo Oliveira
    • 3
  • Luís Belo
    • 1
    • 4
  • Américo Figueiredo
    • 3
  • Petronila Rocha-Pereira
    • 1
    • 5
  • Alice Santos-Silva
    • 1
    • 4
  1. 1.Instituto de Biologia Molecular e Celular (IBMC)Universidade do PortoPortoPortugal
  2. 2.Centro de Investigação das Tecnologias da Saúde (CITS)Instituto Politécnico da Saúde Norte (IPSN)-CESPUGandra-ParedesPortugal
  3. 3.Serviço de DermatologiaHospitais da Universidade de CoimbraCoimbraPortugal
  4. 4.Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
  5. 5.Centro de Investigação em Ciências da Saúde (CICS)Universidade da Beira InteriorCovilhãPortugal

Personalised recommendations